What was known before {#section11-2054358120938573}
=====================

Although most cases of Coronavirus Disease 2019 (COVID-19) are asymptomatic or relatively benign, several patients may be severely affected by the disease, leading to multiple organ failure. The susceptibility to clinical deterioration remains uncertain; however, the risk is higher in patients with specific comorbidities. The mechanism of COVID-19-induced multiorgan failure and the magnitude of the impact on prognosis remain uncertain.

What this adds {#section12-2054358120938573}
==============

The presence of acute kidney injury, acute liver injury, or coagulopathy may be used as a marker for poor prognosis in COVID-19. Early identification and intervention are warranted, especially in the presence of acute kidney injury, which is associated with a 10-fold risk of poorer outcomes.

Introduction {#section13-2054358120938573}
============

The World Health Organization has declared Coronavirus Disease 2019 (COVID-19) as a global public health emergency and a worldwide pandemic. To date, more than 2 million cases and 140 000 deaths have been attributed to COVID-19.^[@bibr1-2054358120938573]^ While most COVID-19 cases are asymptomatic or only display mild influenza-like symptoms, a significant number of patients may experience severe pneumonia, acute respiratory distress syndrome, multiple organ failure, and even death.^[@bibr2-2054358120938573]^ Although it is known that patients with comorbidities are more susceptible to clinical deterioration, the underlying causes remain uncertain.^[@bibr3-2054358120938573][@bibr4-2054358120938573][@bibr5-2054358120938573]-[@bibr6-2054358120938573]^ Emerging evidence suggests that this virus may directly invade human extrapulmonary organs and tissues or induce hyperinflammation mediated by cytokine release, culminating in multiple organ dysfunction, including acute kidney injury (AKI), acute liver injury (ALI), or coagulopathy.^[@bibr7-2054358120938573]^

Currently, there is no specific cure for COVID-19. Government officials around the globe highlighted the importance of old-style public health measures, such as isolation, quarantine, social distancing, and community containment.^[@bibr7-2054358120938573]^ Meanwhile, abnormalities in hematologic, biochemical, and immunologic biomarkers are shown to be associated with severity and mortality in COVID-19.^[@bibr7-2054358120938573]^ Therefore, early evaluation and monitoring of both liver and kidney functions, as well as hematologic parameters, are pivotal for predicting the progression of COVID-19. We, therefore, conducted a systematic review and meta-analysis to explore the association between several complications, including AKI, ALI, and coagulopathy, with poor outcomes in COVID-19. We hypothesized that AKI, ALI, and coagulopathy would be associated with mortality, the need for admission to intensive care, and severe COVID-19.

Methods {#section14-2054358120938573}
=======

This systematic review and meta-analysis followed the Meta-analysis of Observational Studies in Epidemiology reporting guidelines.

Eligibility Criteria {#section15-2054358120938573}
--------------------

The following types of articles were included: research articles in which samples were adult individuals with COVID-19 diagnosis who had information about AKI, ALI, or coagulopathy and the outcome of the clinically validated definition of death, severe COVID-19, or intensive care unit (ICU) care. Both published studies and preprints were included in this systematic review. We excluded abstract-only publications, review articles, commentaries, letters, case reports, and non-English language articles. Studies that did not report key exposures or outcomes of interest were excluded.

Search Strategy and Study Selection {#section16-2054358120938573}
-----------------------------------

A comprehensive systematic literature search was conducted using PubMed, SCOPUS, EuropePMC, and the Cochrane Central Database with keywords (1) "COVID-19" OR "SARS-CoV-2" AND "Characteristics," (2) "COVID-19" OR "SARS-CoV-2" AND "Acute kidney injury," (3) "COVID-19" OR "SARS-CoV-2" AND "liver injury," (4) "COVID-19" OR "SARS-CoV-2" AND "coagulopathy" on April 11, 2020. The PubMed (MEDLINE) search strategy was ("COVID-19"\[All Fields\] OR "SARS-CoV-2"\[All Fields\] AND "Characteristics"\[All Fields\]) OR ("COVID-19"\[All Fields\] OR "SARS-CoV-2"\[All Fields\] AND ("Acute kidney injury"\[All Fields\] OR "Renal dysfunction"\[All Fields\]) OR ("COVID-19"\[All Fields\] OR "SARS-CoV-2"\[All Fields\] AND "liver injury"\[All Fields\]) OR ("COVID-19"\[All Fields\] OR "SARS-CoV-2"\[All Fields\] AND "coagulopathy"\[All Fields\]). The complete search strategy is shown in [supplemental Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2054358120938573). Data searching from several preprint databases (medRvix, ResearchSquare, Preprints) and hand searching were also conducted. Duplicate articles were removed, and the titles and abstracts of the remaining articles were independently screened by 2 authors based on the inclusion and exclusion criteria. Both literature searchers are medical doctors who are experienced in performing systematic reviews and meta-analyses.

Data Extraction {#section17-2054358120938573}
---------------

Data extraction was conducted by 2 independent authors using standardized extraction forms that included author, year, study design, age, sex, cardiovascular diseases, diabetes mellitus, hypertension, respiratory comorbidities, chronic kidney disease (CKD), mortality, severe COVID-19, and the need for ICU care.

Both AKI and ALI follow the definition of the included studies. Coagulopathy refers to the included studies' defined coagulopathy or disseminated intravascular coagulation.

The outcome of interest was a composite of mortality, ICU care, and severe COVID-19. The definition of acute respiratory distress syndrome was established based on the World Health Organization interim guidance of severe acute respiratory infection of COVID-19, which includes acute onset, chest imaging and origin of pulmonary infiltrates, and impairment of oxygenation.^[@bibr7-2054358120938573]^ Severe COVID-19 was diagnosed if individuals had (1) respiratory distress (≥30 breaths per min), (2) resting oxygen saturation ≤93%, (3) ratio of the partial pressure of arterial oxygen (PaO~2~) to the fractional concentration of oxygen inspired air (fiO~2~) ≤300 mm Hg, or (4) critical complication (respiratory failure, septic shock, and multiple organ dysfunction/failure).^[@bibr9-2054358120938573]^

The risk of bias of the included studies was assessed using the Newcastle-Ottawa Score by 2 independent authors and discrepancies were resolved via discussion.

Statistical Analysis {#section18-2054358120938573}
--------------------

Review Manager 5.3 (Cochrane Collaboration) and Stata version 16 were used for statistical analysis. The Mantel-Haenszel formula with random-effects models regardless of heterogeneity was used for dichotomous variables to calculate risk ratios (RRs). All *P* values were 2-tailed, and statistical significance was set at ≤.05. Heterogeneity was assessed using *I*^2^, with a value of \>50% or *P* \< .10, indicating a statistically significant heterogeneity. Random effects meta-regression was conducted using a restricted-maximum likelihood for age, sex, cardiovascular disease, hypertension, diabetes mellitus, and respiratory comorbidities; the analysis was performed for one covariate at a time to avoid overfitting. In assessing the small study effect, a regression-based Harbord's test for binary outcome was performed. An inverted funnel plot analysis was conducted to evaluate the risk of publication bias.

Results {#section19-2054358120938573}
=======

Study Selection and Characteristics {#section20-2054358120938573}
-----------------------------------

There were a total of 1132 records, and 592 remained after the removal of duplicates. A total of 549 records were excluded after screening the titles and abstracts because the records were (1) review articles, letters, and case reports; (2) non-English language articles; or (3) studies that did not report in terms of the outcome of interest. After assessing 43 full-text articles for eligibility, we excluded 28 full-text articles because there were no data on AKI, ALI, or coagulopathy/disseminated intravascular coagulation. We included 15 studies in the qualitative synthesis and meta-analysis ([Figure 1](#fig1-2054358120938573){ref-type="fig"}). A total of 3615 patients from 15 studies were collected.^[@bibr10-2054358120938573],[@bibr11-2054358120938573],[@bibr12-2054358120938573][@bibr13-2054358120938573][@bibr14-2054358120938573][@bibr15-2054358120938573][@bibr16-2054358120938573][@bibr17-2054358120938573][@bibr18-2054358120938573][@bibr19-2054358120938573][@bibr20-2054358120938573][@bibr21-2054358120938573][@bibr22-2054358120938573][@bibr23-2054358120938573]-[@bibr24-2054358120938573]^ The characteristics of the included studies are displayed in [Table 1](#table1-2054358120938573){ref-type="table"}. A total of 7 of the 15 studies were preprints. The characteristics and definition of exposure and the outcome of interest are presented in [Table 2](#table2-2054358120938573){ref-type="table"}. The mean Newcastle-Ottawa scale of the included studies was 7.3 ± 1.2 indicating a moderate risk of bias ([Supplemental Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2054358120938573)).

![PRISMA flow chart.\
*Note.* PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](10.1177_2054358120938573-fig1){#fig1-2054358120938573}

###### 

Characteristics of the Included Studies.

![](10.1177_2054358120938573-table1)

  Study                                       Study design           Preprint    Subjects     Male                 Overall age (mean/median), y   Hypertension        Coronary artery disease/cardiovascular disease   Diabetes           Chronic kidney disease   Respiratory comorbidities   Baseline creatinine (mean/median), μmol/L
  ------------------------------------------- ---------------------- ----------- ------------ -------------------- ------------------------------ ------------------- ------------------------------------------------ ------------------ ------------------------ --------------------------- -------------------------------------------
  Bai et al.^[@bibr10-2054358120938573]^      Retrospective Cohort   Yes         36 vs 91     28/36 vs 52/91       67 vs 50                       15/36 vs 21/91      2/36 vs 1/91                                     5/36 vs 10/91      N/A                      N/A                         N/A
  Cao et al.^[@bibr11-2054358120938573]^      Retrospective Cohort   No          17 vs 85     13/17 vs 40/85       72 vs 53                       11/17 vs 17/85      3/17 vs 2/85                                     6/17 vs 5/85       3/17 vs 1/85             4/17 vs 6/85                N/A
  Chen et al.^[@bibr12-2054358120938573]^     Retrospective Cohort   Yes         31 vs 92     22/31 vs 39/92       72 vs 53                       15/31 vs 26/92      8/31 vs 7/92                                     6/31 vs 8/92       2/31 vs 5/92             3/31 vs 3/92                150 vs 67.8
  Chen et al.^[@bibr13-2054358120938573]^     Retrospective Cohort   No          113 vs 161   83/113 vs 88/161     68.0 vs 51.0                   54/113 vs 39/161    16/113 vs 7/161                                  24/113 vs 23/161   4/113 vs 1/161           11/113 vs 7/161             88 vs 66
  Luo et al.^[@bibr14-2054358120938573]^      Retrospective Cohort   Yes         100 vs 303   57/100 vs 136/303    71 vs 49                       60/100 vs 53/303    16/100 vs 20/303                                 25/100 vs 32/303   3/100 vs 4/303           17/100 vs 11/303            82 vs 68
  Yang et al.^[@bibr23-2054358120938573]^     Retrospective Cohort   No          32 vs 20     21/32 vs 14/20       64.6 vs 51.9                   N/A                 3/32 vs 2/20                                     7/32 vs 2/20       N/A                      2/32 vs 2/20                80.7 vs 76.3
  Zhou et al.^[@bibr15-2054358120938573]^     Retrospective Cohort   No          54 vs 137    38/54 vs 81/137      69.0 vs 52.0                   26/54 vs 32/137     13/54 vs 2/137                                   17/54 vs 19/137    2/54 vs 0/137            4/54 vs 2/137               N/A
  Guan^[@bibr16-2054358120938573]^            Retrospective Cohort   No          173 vs 926   100/173 vs 537/926   52.0 vs 45.0                   41/173 vs 124/926   10/173 vs 17/926                                 28/173 vs 53/926   3/173 vs 5/926           6/173 vs 6/926              N/A
  Hu et al.^[@bibr17-2054358120938573]^       Retrospective Cohort   Yes         172 vs 151   91/172 vs 75/151     65 vs 56                       66/172 vs 39/151    33/172 vs 8/151                                  33/172 vs 14/151   3/172 vs 4/151           6/172 vs 0/151              N/A
  Li et al.^[@bibr24-2054358120938573]^       Retrospective Cohort   Yes         26 vs 299    20/26 vs 147/299     65 vs 49                       12/26 vs 66/299     5/26 vs 13/299                                   5/26 vs 25/299     2/26 vs 2/299            2/26 vs 2/299               80 vs 62
  Liu et al.^[@bibr18-2054358120938573]^      Prospective Cohort     Yes         17 vs 44     10/17 vs 21/44       56 vs 41                       6/17 vs 6/44        1/17 vs 0/44                                     3/17 vs 2/44       N/A                      3/17 vs 2/44                64 vs 56.5
  Wan et al.^[@bibr20-2054358120938573]^      Retrospective Cohort   No          40 vs 95     21/40 vs 52/95       56 vs 44                       4/40 vs 9/95        6/40 vs 1/95                                     9/40 vs 3/95       N/A                      1/40 vs 0/95                63.5 vs 66
  Zhang et al.^[@bibr19-2054358120938573]^    Retrospective Cohort   Yes         55 vs 166    35/55 vs 73/166      62 vs 51                       26/55 vs 28/166     13/55 vs 9/166                                   7/55 vs 15/166     5/55 vs 1/166            4/55 vs 2/166               75 vs 67
  Huang, et al.^[@bibr22-2054358120938573]^   Retrospective Cohort   No          13 vs 28     11/13 vs 19/28       49.0 vs 49.0                   2/13 vs 4/28        3/13 vs 3/28                                     1/13 vs 7/28       N/A                      1/13 vs 0/28                79 vs 73.3
  Wang et al.^[@bibr21-2054358120938573]^     Retrospective Cohort   36 vs 102   36 vs 102    22/36 vs 53/102      66 vs 51                       21/36 vs 22/102     9/36 vs 11/102                                   8/36 vs 6/102      2/36 vs 2/102            3/36 vs 1/102               80 vs 71

*Note.* Data are presented stratified by those with outcome of interest vs. those without outcome of interest. N/A = not available.

###### 

Characteristics of Exposures and Outcome of the Included Studies.

![](10.1177_2054358120938573-table2)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                      Defintion of confirmed COVID-19                         Outcome of interest   Definition of severe COVID-19                                             Started in ICU, %   AKI                Definition of AKI   ALI                Definition of ALI                                                                                   Coagulopathy      Definition of coagulopathy                                                 Newcastle-Ottawa scale
  ------------------------------------------ ------------------------------------------------------- --------------------- ------------------------------------------------------------------------- ------------------- ------------------ ------------------- ------------------ --------------------------------------------------------------------------------------------------- ----------------- -------------------------------------------------------------------------- ------------------------
  Bai et al.^[@bibr10-2054358120938573]^     \+ RT-PCR SARS-CoV-2                                    Mortality             N/A                                                                       N/A                 12/36 vs 0/91      KDIGO               9/36 vs 1/91       N/A                                                                                                 14/36 vs 0/91     N/A                                                                        9

  Cao et al.^[@bibr11-2054358120938573]^     \+ RT-PCR SARS-CoV-2                                    Mortality             N/A                                                                       17.6                15/17 vs 5/85      N/A                 13/17 vs 21/85     N/A                                                                                                 N/A               N/A                                                                        7

  Chen et al.^[@bibr12-2054358120938573]^    \+ RT-PCR SARS-CoV-2                                    Mortality             N/A                                                                       N/A                 15/31 vs 3/92      KDIGO               6/31 vs 13/92      Increased ALT \>2× UNL without preexisting chronic liver disease and Drug-induced liver injury      24/31 vs 18/92    Abnormal PT, APTT, D-dimer, and platelet, excluding anticoagulant effect   9

  Chen et al.^[@bibr13-2054358120938573]^    \+ RT-PCR SARS-CoV-2                                    Mortality             Severe: Chinese NHC (not defined)                                         N/A                 28/113 vs 1/161    KDIGO               10/113 vs 3/161    Jaundice with a total bilirubin level of ≥3 mg/dL and increased ALT ≥5× UNL and/or increased ALP\   19/113 vs 2/161   DIC                                                                        7
                                                                                                                                                                                                                                                                                   ≥2 UNL                                                                                                                                                                                           

  Luo et al.^[@bibr14-2054358120938573]^     \+ RT-PCR SARS-CoV-2                                    Mortality             N/A                                                                       N/A                 43/100 vs 14/303   N/A                 71/100 vs 16/303   N/A                                                                                                 N/A               N/A                                                                        7

  Yang et al.^[@bibr23-2054358120938573]^    \+ RT-PCR SARS-CoV-2                                    Mortality             N/A                                                                       100                 12/32 vs 3/20      KDIGO               9/32 vs 6/20       N/A                                                                                                 N/A               N/A                                                                        7

  Zhou et al.^[@bibr15-2054358120938573]^    \+ RT-PCR SARS-CoV-2                                    Mortality             Severe: Chinese NHC (not defined)                                         26                  27/54 vs 1/137     KDIGO               N/A                N/A                                                                                                 27/54 vs 10/137   3-second extension of PT or 5-second extension of APTT                     9

  Guan^[@bibr16-2054358120938573]^           \+ RT-PCR SARS-CoV-2                                    Severe COVID-19       Severe: American Thoracic Society (on admission)                          5                   5/173 vs 1/926     KDIGO               N/A                N/A                                                                                                 5/173 vs 1/926    DIC                                                                        6

  Hu et al.^[@bibr17-2054358120938573]^      Clinical with Radiological and/or + RT-PCR SARS-CoV-2   Severe COVID-19       Severe: Chinese- World Health Organization Joint Mission (on admission)   N/A                 15/172 vs 2/151    N/A                 N/A                N/A                                                                                                 N/A               N/A                                                                        8

  Li et al.^[@bibr24-2054358120938573]^      \+ RT-PCR SARS-CoV-2                                    Severe COVID-19       Severe: Chinese NHC (not defined)                                         N/A                 7/26 vs 12/299     KDIGO               N/A                N/A                                                                                                 N/A               N/A                                                                        6

  Liu et al.^[@bibr18-2054358120938573]^     Clinical with Laboratory Confirmation                   Severe COVID-19       Severe: Chinese NHC (at the end of study)                                 13.1                N/A                N/A                 N/A                N/A                                                                                                 N/A               N/A                                                                        9

  Wan et al.^[@bibr20-2054358120938573]^     \+ RT-PCR SARS-CoV-2                                    Severe COVID-19       Severe: Chinese NHC (not defined)                                         N/A                 1/40 vs 4/95       N/A                 N/A                N/A                                                                                                 N/A               N/A                                                                        6

  Zhang et al.^[@bibr19-2054358120938573]^   \+ RT-PCR SARS-CoV-2                                    Severe COVID-19       Severe: Chinese NHC (on admission)                                        31.9                8/55 vs 2/166      KDIGO               N/A                N/A                                                                                                 N/A               N/A                                                                        6

  Huang, 2020                                \+ RT-PCR SARS-CoV-2                                    ICU Care              N/A                                                                       N/A                 3/13 vs 0/28       KDIGO               N/A                N/A                                                                                                 N/A               N/A                                                                        7

  Wang et al.^[@bibr21-2054358120938573]^    \+ RT-PCR SARS-CoV-2                                    ICU Care              N/A                                                                       N/A                 3/36 vs 2/102      KDIGO               N/A                N/A                                                                                                 N/A               N/A                                                                        7
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* Data are presented stratified by those with outcome of interest vs. those without outcome of interest. The mean Newcastle-Ottawa scale of the included studies was 7.3 ± 1.2 indicating a moderate risk of bias. COVID-19 = Coronavirus Disease 2019; ICU = intensive care unit; AKI = acute kidney injury; ALI = acute liver injury; RT-PCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus-2; N/A = not available; KDIGO = Kidney Disease Improving Global Outcomes; ALT = alanine aminotransferase; UNL = upper normal limit; PT = prothrombin time; APTT = activated partial thromboplastin time; NHC = National Health Commission; DIC = disseminated intravascular coagulation.

AKI and Poor Outcome {#section21-2054358120938573}
--------------------

Acute kidney injury was associated with increased the composite outcome (RR: 10.55 \[7.68, 14.50\], *P* \< .001; *I*^2^: 0%, *P* = .49) ([Figure 2A](#fig2-2054358120938573){ref-type="fig"}). Subgroup analysis demonstrated that AKI was associated with increased mortality (RR: 13.38 \[8.15, 21.95\], *P* \< .001; *I*^2^: 24%, *P* = .25), severe COVID-19 (RR: 8.12 \[4.43, 14.86\], *P* \< .001; *I*^2^: 0%, *P* = .73), and the need for ICU care (RR: 5.90 \[1.32, 26.35\], *P* = .02; *I*^2^: 0%, *P* = .49). Acute kidney injury was still associated with the composite outcome after exclusion of studies that did not report baseline serum creatinine (RR: 9.19 \[6.36, 13.27\], *P* \< .001; *I*^2^: 0%, *P* = .74) in patients with AKI.

![(A) Acute kidney injury was associated with increased the composite outcome, (B) acute liver injury was associated with increased mortality, and (C) mortality was higher in Coronavirus Disease 2019 patients with coagulopathy.\
*Note.* CI = confidence interval.](10.1177_2054358120938573-fig2){#fig2-2054358120938573}

ALI and Mortality {#section22-2054358120938573}
-----------------

Acute liver injury was associated with increased mortality (RR: 4.02 \[1.51, 10.68\], *P* = .005; *I*^2^: 88%, *P* \< .001) in COVID-19 patients ([Figure 2B](#fig2-2054358120938573){ref-type="fig"}).

Coagulopathy {#section23-2054358120938573}
------------

Mortality was higher in COVID-19 patients with coagulopathy (RR: 7.55 \[3.24, 17.59\], *P* \< .001; *I*^2^: 69%, *P* = .02) ([Figure 2C](#fig2-2054358120938573){ref-type="fig"}).

Meta-Regression {#section24-2054358120938573}
---------------

The association between AKI and increased the composite outcome was not influenced by age (*P* = .182) ([Figure 3A](#fig3-2054358120938573){ref-type="fig"}), sex (*P* = .104), hypertension (*P* = .788), cardiovascular diseases (*P* = .068) ([Figure 3B](#fig3-2054358120938573){ref-type="fig"}), diabetes (*P* = .097), respiratory comorbidity (*P* = .762), and CKD (*P* = .77).

![Meta-regression analysis. The association between acute liver injury and increased the composite outcome was not influenced by (A) age or (B) cardiovascular disease.\
*Note.* CI = confidence interval; CAD = coronary artery disease; CVD = cardiovascular disease.](10.1177_2054358120938573-fig3){#fig3-2054358120938573}

Publication Bias {#section25-2054358120938573}
----------------

The funnel plot analysis demonstrated an asymmetrical shape for AKI ([Figure 4](#fig4-2054358120938573){ref-type="fig"}). There was no indication of small-study effects for the association between AKI and increased composite outcome (*P* = .117). There was no indication of small-study effects for the association of ALI (*P* = .122) and coagulopathy (*P* = .227) with mortality.

![Publication bias. The funnel plot analysis showed an asymmetrical inverted funnel plot shape for acute kidney injury.\
*Note.* CI = confidence interval.](10.1177_2054358120938573-fig4){#fig4-2054358120938573}

Discussion {#section26-2054358120938573}
==========

This meta-analysis showed that AKI was associated with poor composite outcomes, including mortality, severe COVID-19, and the need for ICU care in COVID-19 patients. This association was not significantly influenced by gender, age, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, and CKD. Moreover, ALI and coagulopathy were also associated with increased mortality in patients with COVID-19. Five studies did not report baseline serum creatinine levels. Nevertheless, the exclusion of the aforementioned studies in the sensitivity analysis showed a consistent conclusion. The heterogeneity of ALI and coagulopathy was probably caused by the varying definitions used in the studies, which were not reported.

Qualitative risk of bias analysis indicated a moderate to high risk of bias in the included studies. These were mostly attributed to low comparability; the included studies were not specifically designed to evaluate AKI as a risk factor for mortality. Many of the studies only reported their findings in COVID-19 patients and were not geared toward determining whether the risk factors are independent of each other. Furthermore, we also recognized that the number of events/exposures in the studies was low; hence, the adjusted analysis might cause model overfitting. The quantitative risk of bias analysis showed the possibility of publication bias for the AKI outcome. There was no indication of small-study effects for any outcome.

Although SARS-CoV-2 primarily invades the human respiratory tract, there are indications of extrapulmonary organ involvement. Such manifestations may be directly caused by SARS-CoV-2 or due to medications used in the treatment of the infection. COVID-19 has 3-dimensional structure spike proteins, which are tightly bound to angiotensin-converting enzyme 2 (ACE2) following the activation of spike protein by transmembrane protease serine 2 (TMPRSS2).^[@bibr25-2054358120938573],[@bibr26-2054358120938573]^ Hence, cells that express ACE2 become target cells that are prone to viral intrusion. Vulnerable cells include, but are not limited to, pulmonary alveolar cells type II, kidney tubular epithelial cells, liver endothelial cells, cardiac epithelial cells and artery smooth muscle cells, intestinal epithelial cells, and the gastrointestinal system. Therefore, it is plausible to assume multiorgan viral invasion in COVID-19, viremia may cause pneumonia, acute cardiac injury, diarrhea, ALI, and AKI.^[@bibr27-2054358120938573][@bibr28-2054358120938573][@bibr29-2054358120938573]-[@bibr30-2054358120938573]^ Furthermore, microvesicular steatosis and liver injury have been reported in the liver biopsy of some patients with COVID-19 pneumonia, suggesting possible damage from either viral invasion or drug-induced hepatic injury.^[@bibr31-2054358120938573]^

Podocytes and proximal straight tubule cells are identified as kidney host cells for COVID-19 infection with the expression of ACE2 receptors, and *TMPRSS2* genes were no less in kidney cells than in the lung, esophagus, small intestine, and colon.^[@bibr26-2054358120938573],[@bibr32-2054358120938573],[@bibr33-2054358120938573]^ Playing a crucial role in urine filtration, reabsorption, and excretion, these cells are susceptible to both bacterial and viral damage, and podocyte injury swiftly causes heavy proteinuria.^[@bibr32-2054358120938573][@bibr33-2054358120938573]-[@bibr34-2054358120938573]^ Viral-induced cytopathic effects may cause AKI in COVID-19, particularly in patients with evidence of viremia. This suggests the importance of early monitoring of kidney function and careful handling of laboratory specimens from COVID-19 patients with AKI to prevent accidental transmission.^[@bibr26-2054358120938573]^

Cytokine release syndrome, rather than active viral replication in the kidney, is thought to be one of the pathomechanisms underlying AKI in COVID-19. Increased viral load in pneumocytes leads to remarkable immune responses, which generate a large number of cytokines leading to multiple organ dysfunction. It is also reasonable to assume that COVID-19 may infect the human kidney directly, causing AKI and massive viral invasion spreading in the body.^[@bibr35-2054358120938573]^

Liver injury in COVID-19 might be due to direct viral invasion in liver cells, drug hepatotoxicity, or immune-mediated inflammation, including cytokine storm and hypoxia-related pneumonia.^[@bibr36-2054358120938573],[@bibr37-2054358120938573]^ Both liver endothelial cells and bile duct epithelial cells express ACE2, with the latter expressing far higher levels of ACE2 than the former, but to a level comparable with that of type II alveolar cells in the lung.^[@bibr37-2054358120938573]^ Bile duct epithelial cells play a significant role in immune response and liver regeneration, suggesting that the virus may affect bile duct cells rather than liver cells.^[@bibr38-2054358120938573]^ Multiple studies have reported that patients with severe COVID-19 seem to have higher rates of liver dysfunction, as indicated by abnormal levels of alanine aminotransferase and aspartate aminotransferase accompanied by slightly elevated bilirubin and occasionally decreased albumin during disease progression.^[@bibr2-2054358120938573],[@bibr23-2054358120938573],[@bibr22-2054358120938573],[@bibr39-2054358120938573][@bibr40-2054358120938573][@bibr41-2054358120938573]-[@bibr42-2054358120938573]^ Although liver damage in mild COVID-19 cases is mostly transient and reversible, severe and critical cases tend to develop more advanced liver injury and even progress to liver failure. Such conditions require intervention to protect liver function and inhibit inflammatory responses.^[@bibr38-2054358120938573],[@bibr43-2054358120938573]^

Severe COVID-19 pneumonia may coexist with coagulopathy, such as disseminated intravascular coagulation and venous thromboembolism.^[@bibr44-2054358120938573]^ Endothelial cell dysfunction, together with the activation of platelets and leukocytes, leads to excessive thrombin production and fibrinolysis shutdown, which occurs both systemically and locally in the respiratory tract of patients with severe pneumonia, causing fibrin deposition along with subsequent tissue injury and microangiopathic pathology.^[@bibr45-2054358120938573]^ Moreover, hypoxia occurring in severe pneumonia may promote thrombosis via increased blood viscosity and the hypoxia-induced transcription factor--dependent signaling pathway. These mechanisms might explain the hypercoagulable state observed in patients with severe COVID-19 pneumonia.^[@bibr44-2054358120938573]^ Severe COVID-19 is also associated with increased platelet count, markedly elevated D-dimer values, longer prothrombin time, and lower fibrinogen and antithrombin activity.^[@bibr44-2054358120938573][@bibr45-2054358120938573]-[@bibr46-2054358120938573]^ These findings suggest that abnormal coagulation parameters during the course of the disease are associated with poor prognosis.^[@bibr46-2054358120938573]^

Formulating from the implications drawn from this systematic review and meta-analysis, we suggest several strategies for clinical practice; the presence of AKI, ALI, or coagulopathy may be used as markers for poor prognosis in COVID-19. Early identification and intervention are suggested, especially in the presence of AKI, where its presence is associated with a 10-fold risk of poor outcome. Regular monitoring for early identification and timely intervention of these complications is suggested, especially in treating patients with severe COVID-19. We suggest specific supportive measures in critically ill patients, including tight control of fluid balance and circulatory support, nutritional therapy, and deep vein thrombosis prophylaxis.^[@bibr47-2054358120938573]^ Until solid evidence regarding specific drug therapy in COVID-19 emerge, we also recommend the use of fewer medications and withhold any drugs that could induce hepatic or kidney injury.

There are several limitations of this study. Many of these studies did not define the extent of AKI (grade), which may affect the outcome. Liver injury and coagulopathy were not defined in most of the studies. The definition of severe COVID-19 differs across studies. Several articles included in the study were published at preprint servers, which are not yet peer-reviewed. Most of the studies were from China; thus, some patients might overlap across the reports. Most of the included studies were retrospective in design.

Conclusions {#section27-2054358120938573}
===========

This meta-analysis showed that the presence of AKI, ALI, and coagulopathy was associated with the composite outcome in patients with COVID-19. Due to the high risk of bias and poor comparability of the included studies, the effect estimate may not reflect the magnitude of the true effect. Other comorbidities or complications that may lead to poor outcomes, potentially confounding the effect estimate. Future research is encouraged to provide adjustment for their analysis and create a prediction model that includes AKI, ALI, and coagulopathy. We also encourage future research to investigate the risk factors associated with AKI, ALI, and coagulopathy in COVID-19 patients to aid drug considerations. Finally, we encourage studies to investigate the efficacy of additional measures for patients with multiorgan dysfunction, such as anticoagulants.
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